Supplementary Table I. Malignancies during the cumulative study period.

Type of malignant neoplasm, n (%)	Cumulative period[a] (All treatment groups combined, baseline to Year 7, n=287)	Mean time to onset, days
Non-melanoma skin cancer	12 (4.2)	
Basal cell carcinoma	6 (2.1)	995
Squamous cell carcinoma	5 (1.7)	999
Bowen's disease	1 (0.3)	1276
Solid organ malignancies	11 (3.8)	
Malignant lung neoplasm	2 (0.7)	1271
Bladder cancer	1 (0.3)	203
Bladder transitional cell carcinoma	1 (0.3)	2010
Breast cancer	1 (0.3)	1443
Colon neoplasm	1 (0.3)	2322
Lung adenocarcinoma	1 (0.3)	484
Metastatic lung cancer	1 (0.3)	1596
Ovarian cancer	1 (0.3)	976
Prostate neoplasm	1 (0.3)	813
Small cell lung cancer	1 (0.3)	1371
Haematologic malignancy (light chain disease)	1 (0.3)	2478

[a]All patients who were originally randomised to IV abatacept (10 or 2 mg/kg), plus MTX, and received one dose, plus all patients who were originally randomised to placebo and entered the long-term extension (and subsequently received one dose of IV abatacept, plus MTX). Data includes events occurring up to 60 days after last infusion.
IV: intravenous; MTX: methotrexate.

Supplementary Table II. Autoimmune events during the cumulative study period.

Autoimmune event, n (%)	Cumulative period[a] (All treatment groups combined, baseline to Year 7, n=287)
Psoriasis	7 (2.4)
Cutaneous vasculitis	2 (0.7)
Erythema nodosum	2 (0.7)
Multiple sclerosis	1 (0.3)
Rheumatoid vasculitis	1 (0.3)
Sicca syndrome	1 (0.3)

[*]All patients who were originally randomised to IV abatacept (10 or 2 mg/kg), plus MTX, and received one dose, plus all patients who were originally randomised to placebo and entered the long-term extension (and subsequently received one dose of IV abatacept, plus MTX). Data includes events occurring up to 60 days after last infusion.
IV: intravenous; MTX: methotrexate.